Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay Cilansetron NDA "Not Approvable" For Irritable Bowel Syndrome

This article was originally published in The Pink Sheet Daily

Executive Summary

The "not approvable" letter requests additional clinical trials as well as changes to some non-clinical items, Solvay says. The company says it has informed FDA of its intent to amend the application.

You may also be interested in...



Solvay Withdraws NDA For IBS Agent Cilansetron

The company points to the burden of additional clinical work requested by FDA and a weak potential market for the irritable bowel syndrome product.

Solvay Withdraws NDA For IBS Agent Cilansetron

The company points to the burden of additional clinical work requested by FDA and a weak potential market for the irritable bowel syndrome product.

Solvay Preparing Announcement On Cilansetron NDA

Solvay receives a response letter from FDA one week ahead of the user fee deadline for the irritable bowel syndrome product. Solvay is currently assessing the letter's contents, the company says.

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel